Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.